MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.
This year has seen Germany’s BioNTech achieve a truly remarkable feat of working with Pfizer to bring more than two billion doses of their mRNA-based COVID-19 vaccine to the world, saving millions from hospitalization or death and altering the course of the still-ongoing pandemic.
The companies priced Comirnaty at around $20 per shot in developed nations and its safety,efficacy and availability at scale have allowed them to reap the commercial rewards, expected
At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
Vyepti revenues rise by nearly 70% in the first quarter.
